A SIMPLE KEY FOR MOUNJARO INJECTION 2.5 MG UNVEILED

The trial realized the two its Most important endpoints, with semaglutide two.4 mg demonstrating statistically sizeable and remarkable improvements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH as compared to placebo.1Hold all appointme